Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Alchemia Limited, today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC). Two patients have received their first doses of therapy. This investigator sponsored trial is being conducted at Monash Cancer Centre, Southern Health and Peninsula Oncology Centre in Melbourne, Victoria.

12 Sep 2011

Genentech submits NDA to FDA for vismodegib to treat advanced basal cell carcinoma

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its collaborator Genentech, a member of the Roche Group, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking sales and marketing approval for vismodegib to treat people with advanced basal cell carcinoma (BCC), which includes metastatic and locally advanced BCC for whom surgery is inappropriate.

12 Sep 2011

Genentech submits vismodegib NDA to FDA for treatment of advanced basal cell carcinoma

Genentech, a member of the Roche Group, today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

12 Sep 2011

ATA announces five recipients of 2011 thyroid cancer research grants

The American Thyroid Association (ATA) announced the five recipients of its 2011 research grants, each of whom will receive up to $25,000 annually for up to two years. Three of the five recipients were awarded special ATA ThyCa grants for research projects that focus on thyroid cancer. These grants are funded by ThyCa: Thyroid Cancer Survivors, Inc.

8 Sep 2011

BCH joins MD Anderson's Sister Institution network to provide cancer care

Today, Barretos Cancer Hospital (BCH) in Brazil joined The University of Texas MD Anderson Cancer Center's Sister Institution network. In a signing ceremony at BCH's newly opened Research Institute Against Digestive Cancer (IRCAD-Brazil), MD Anderson provost and executive vice president, Raymond DuBois, M.D., Ph.D., marked the beginning of an alliance that will allow the two institutions to build a number of collaborative research projects and academic interactions.

8 Sep 2011

Ardea Biosciences reports positive outcome from lesinurad End-of-Phase 2 meetings with FDA

Ardea Biosciences, Inc. announced that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and successfully reached agreement on the following key aspects of its proposed lesinurad Phase 3 development plan: the overall size and design of the planned Phase 3 clinical studies, the primary endpoints, the total safety database proposed for NDA filing, manufacturing plans for both drug substance and drug product, the preclinical toxicology program and the clinical pharmacology program.

7 Sep 2011

Biologists identify mechanism of H. pylori that damages DNA of gastric mucosal cells

The stomach bacterium Helicobacter pylori is one of the biggest risk factors for the development of gastric cancer, the third most common cause of cancer-related deaths in the world.

6 Sep 2011

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced positive topline data from its Phase II SAPHIRE trial with resminostat, its oral pan HDAC inhibitor, in patients with relapsed/refractory Hodgkin's Lymphoma.

6 Sep 2011

BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer

BioAlliance Pharma SA, a company dedicated to specialty and orphan oncology products, today announces oral communication of the Phase II clinical trial results of its orphan product Livatag at the annual congress of ILCA, the only international organization devoted exclusively to liver cancer research with participation of worldwide best specialists.

6 Sep 2011

Fibrous stroma can help predict aggressiveness of squamous cell carcinoma

The nature of the connective tissue surrounding lung cancer nests can help predict the aggressiveness of squamous cell carcinoma, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer.

2 Sep 2011

Engineered virus shows promise in cancer therapy via bloodstream

Scientists have engineered a virus that when injected into the blood, can selectively target cancer cells throughout the body. The virus attacked only tumours, leaving the healthy tissue alone, in a small trial on 23 patients, according to the journal Nature.

2 Sep 2011

Medical engineers develop sensor chip to monitor cancerous tumors

A surgery is usually one of the first therapy options in cancer treatment. However, some tumors, such as brain tumors, can be difficult to operate on if there is a risk of damaging surrounding nerve tissue.

29 Aug 2011

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

The 2011 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, will convene September 11-14, 2011, in San Francisco, CA.

29 Aug 2011

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.

29 Aug 2011

Neoadjuvant chemotherapy prior to surgery can benefit women with lobular breast cancer

Researchers at the Medical University of Vienna have found that the breast of one in two women with lobular breast cancer can be preserved through chemotherapy prior to a breast operation.

26 Aug 2011

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Symphogen A/S today announced the initiation of a Phase 2 clinical trial to investigate the safety and efficacy of Sym004 in patients who have failed anti-EGFR monoclonal antibody (mAb)-based therapy, with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

23 Aug 2011

Survival for patients with HCC increases with radioembolization

Analysis revealed survival for patients with hepatocellular carcinoma (HCC) is achievable using 90Y-resin microsphere radioembolization. The analysis conducted at multiple centers across Europe showed that the procedure is likely to provide survival benefit across different tumor stages, including patients with advanced liver cancer and with limited treatment options.

23 Aug 2011

Should we be screening blood for hepatisi G?

Hepatitis G virus was identified in 1995. Some little research was carried out on the virus and the US Food and Drug Administration (FDA) declared it a non-harmful virus in 1997. Researchers in Saudi Arabia, writing in the International Journal of Immunological Studies present evidence to suggest that this may have been the wrong decision.

22 Aug 2011

Saffron promotes apoptosis and inhibits growth of cancerous cells

New research suggests that saffron provides a significant chemopreventive effect against liver cancer in animal models. When saffron was administered to rats with diethylnitrosamine (DEN)-induced liver cancer an inhibition of cell proliferation and stimulation of apoptosis was observed. Full findings appear in the September issue of Hepatology, a journal published by Wiley Blackwell on behalf of the American Association for the Study of Liver Diseases.

22 Aug 2011

CEL-SCI receives Chinese patent for Multikine cancer drug

CEL-SCI Corporation today announced that the Chinese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine.

18 Aug 2011

Carcinoma News and Research

Further Reading

Alchemia initiates HA-Irinotecan Phase II clinical study in SCLC

Genentech submits NDA to FDA for vismodegib to treat advanced basal cell carcinoma

Genentech submits vismodegib NDA to FDA for treatment of advanced basal cell carcinoma

ATA announces five recipients of 2011 thyroid cancer research grants

BCH joins MD Anderson's Sister Institution network to provide cancer care

Ardea Biosciences reports positive outcome from lesinurad End-of-Phase 2 meetings with FDA

Biologists identify mechanism of H. pylori that damages DNA of gastric mucosal cells

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer

Fibrous stroma can help predict aggressiveness of squamous cell carcinoma

Engineered virus shows promise in cancer therapy via bloodstream

Medical engineers develop sensor chip to monitor cancerous tumors

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Neoadjuvant chemotherapy prior to surgery can benefit women with lobular breast cancer

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Survival for patients with HCC increases with radioembolization

Should we be screening blood for hepatisi G?

Saffron promotes apoptosis and inhibits growth of cancerous cells

CEL-SCI receives Chinese patent for Multikine cancer drug

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News